Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin is an antibody–drug conjugate comprising a humanized anti‐B‐cell maturation antigen (BCMA) monoclonal antibody conjugated to monomethyl auristatin F (MMAF) via a protease‐resistant maleimidocaproyl linker. Single‐agent belantamab mafodotin showed clinically meaningful activity a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferron‐Brady, Geraldine, Rathi, Chetan, Collins, Jon, Struemper, Herbert, Opalinska, Joanna, Visser, Sandra, Jewell, Roxanne C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293327/
https://www.ncbi.nlm.nih.gov/pubmed/34468979
http://dx.doi.org/10.1002/cpt.2409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293327/
https://www.ncbi.nlm.nih.gov/pubmed/34468979
http://dx.doi.org/10.1002/cpt.2409

Ejemplares similares